Clinical impact and cost-effectiveness of vaccinating infants and adolescents against invasive meningococcal B disease in the Netherlands
The modelled IMD-B vaccination programs resulted in the prevention of limited morbidity and mortality at a high financial burden. The inclusion of any of the evaluated vaccines in the Dutch NIP for infants or adolescents is not cost-effective in any target group at conventional Dutch cost-effectiveness thresholds given current IMD-B incidence levels.
Authors
- Thomas Otten (ORCID: https://orcid.org/0000-0002-6390-5638)
- Anneke Steens (ORCID: https://orcid.org/0000-0002-7474-1149)
- Mirjam J. Knot
- Pieter de Boer
- Lard Montesano Montessori
Institutions
- National Institute for Public Health and the Environment (NL)
Publication Details
- Journal
- BMC Medicine
- Published
- 2026-02-10
- DOI
- https://doi.org/10.1186/s12916-026-04651-z
- Primary Topic
- Bacterial Infections and Vaccines
- Type
- article
- Field-Weighted Citation Impact
- 0.00